Investment Rating - The report maintains a "Buy" rating for the company, with a target price of HKD 44.00, indicating a potential upside of 84.1% from the current price of HKD 23.90 [2][3][10]. Core Insights - The company is expected to achieve profitability again in 2024, driven by strong overseas sales of Furmonertinib and effective cost control measures. The focus for 2025 will be on the NDA submission for SAVANNAH in the US and the expansion of new products and indications in the domestic market [3][7]. - The company reported a revenue of USD 363 million for its oncology/immunology business in 2024, with oncology product revenue increasing by 65% year-on-year to USD 272 million, largely due to the significant sales growth of Furmonertinib in overseas markets [7]. - The report anticipates that overseas sales will grow to USD 460 million in 2025, supported by improved insurance coverage in the US and the commercialization of new markets in Japan and the EU [7]. Financial Forecasts - Revenue projections for 2025 are set at USD 708 million, with a slight decrease from previous estimates. The gross profit is expected to be USD 386 million, reflecting a gross margin of 54.6% [6][12]. - The net profit forecast for 2025 is USD 452 million, representing a significant increase of 15% compared to prior estimates, with a net profit margin of 63.9% [6][12]. - The report outlines a DCF valuation model, projecting a free cash flow of USD 42 million in 2025, with a perpetual growth rate of 3% [8]. Key Catalysts - Upcoming catalysts include the NDA submission for SAVANNAH, approval progress for various indications of Furmonertinib and Savolitinib in the domestic market, and the entry of the first candidate drug from the ATTC platform into clinical trials in the second half of 2025 [7][8].
和黄医药：2024年再次实现盈利，SAVANNAH注册队列数据优异，维持买入评级-20250320